A broad range of psychosocial and psychological interventions have been reported to aid in reducing depression and accompanying anxiety, enhancing coping skills, and improving quality of life in patients with cancer.33-37 In general, more convincing effects are found for patients screened at baseline36,38; however, few studies have targeted patients with depressive disorders,39 and because the majority of studies have been of white women,40 the evidence is relatively weak for other populations.
PharmacotherapyA systematic review by Williams and Dale41 of 24 randomized controlled trials of either pharmacologic or psychotherapeutic interventions for cancer patients with depression or depressive symptoms recently concluded that depression in cancer patients is responsive to antidepressant medication treatment, although some studies reported high dropout rates and some failed to report adverse events or tolerability. For example, paroxetine(Drug information on paroxetine) was useful in reducing major depression in patients with malignant melanoma who were receiving high-dose interferon alpha treatment42 and in reducing depressive symptoms in patients with breast cancer who were undergoing chemotherapy.43 In a trial by Fisch and colleagues,44 fluoxetine(Drug information on fluoxetine) was effective in reducing depressive symptoms in patients with solid tumors.
Other studies not analyzed by Williams and Dale report that the tetracyclic antidepressant mianserin(Drug information on mianserin) reduced depressive symptoms in patients with breast cancer and that tricyclic antidepressants such as amitriptyline(Drug information on amitriptyline) and desipramine are also useful in the treatment of depression in cancer.45,46 An open-label study of mirtazapine(Drug information on mirtazapine) in cancer patients with depression showed improved functionality and reduced depressive and anorexic symptoms.47 The tolerability of the above antidepressants appears to be generally good in patients with cancer. Patients may experience adverse effects, but such effects may be complicated by treatment of the cancer itself.
As already suggested, it is important to consider the treatment implications of simultaneously managing depression and pain and fatigue in patients with cancer using a variety of evidence-based interventions.24,48,49 In addition to alleviating symptoms of depression, antidepressant medications may provide relief of related cancer symptoms. For example, fluoxetine, paroxetine, and venlafaxine have been effective in reducing hot flashes in patients with cancer.50-52 Patients may have neuropathic pain from the cancer or the treatments, and bupropion, the tricyclic antidepressants, and venlafaxine have demonstrated the ability to reduce neuropathic pain.53-55 Avoiding significant drug interactions in patients on complex chemotherapeutic and pain management regimens requires careful monitoring.26,56 The NCI Web site provides detailed pharmacologic treatment algorithms that are consistent with current knowledge.
PsychotherapyThere is growing consensus that structured psychotherapy, alone or combined with antidepressant treatment, is effective in treating depression.57 Under some circumstances, it is the treatment of choice (ie, when preferred by individual patients, when pharmacologic treatments are contraindicated, and for patients coping with low social support or environmental stressors; or for maintenance after discontinuation of antidepressant medication). Clinical benefits from psychotherapy should be evident within 6 to 8 weeks. Medications should be considered for patients who fail to improve by that time and for those who do not have full remission after 12 weeks of psychotherapy. Structured psychosocial therapies are as effective as antidepressants for moderate depression and may be more effective in reducing recurrence.58
In a report based on their systematic review of the literature on psychotherapeutic interventions for people with cancer, Williams and Dale41 concluded that cognitive-behavioral therapy (CBT) appears to be effective, as does social support, in reducing depressive symptoms. CBT challenges pessimistic or self-critical thoughts, emphasizes rewarding activities, and decreases behavior that reinforces depression. Alternative modes of delivery of CBT have been explored, including group CBT and telephone or computer self-help formats.59
Problem-solving therapy (PST) uses behavior activation components of CBT but with less emphasis on changing cognition and greater emphasis on patient assessment of personal contextual problems and skill-building to enhance self-management skills.60 PST adapted for primary care in the multicenter IMPACT study61 was found to significantly reduce depressive symptoms in older primary care patients, including African American and Hispanic patients, with major depression or dysthymia,57 and PST was found effective in reducing depres- sive symptoms in patients with cancer.15,60,62-65 The brief psychoeduca- tional characteristics of PST make it feasible to provide and acceptable to patients with a wide range of educational levels. PST is available in published treatment manuals for depression and for coping with cancer. According to the PST theoretical framework, experiencing negative life events (such as cancer) can lead to the occurrence of a wide range of daily problems that are believed to be sources of stress that trigger depressive symptoms. Increasing problem-solving skills has been shown to reduce depressive symptoms.
REDUCING BARRIERS AND IMPROVING ADHERENCEQuality-improvement strategies have been shown to be effective in reducing barriers to depression care.66 Organizational strategies generally include multifaceted quality-improvement disease-management interventions that change the way in which depression care is delivered, such as the implementation of routine depression screening, systematic application of evidence-based practice guidelines, clinical decision-making protocols and algorithms (cancer-specific algorithms available on the NCI and National Comprehensive Cancer Network Web sites29,30), follow-up through remission and maintenance, enhanced roles of nurses or social workers as depression care managers, as well as integration between primary care and mental health specialists or service systems.67
Depression care models that use collaboration between primary care physicians and mental health professionals, in which expertise in psychopharmacology in treating depression is provided by a psychiatrist and PST and supportive care management is provided by depression specialist nurses or social workers, has been found to be effective in primary care.57 A model adapted for oncology was found to be effective in a pilot study that included 55 low-income Hispanic patients with breast or cervical cancer, all of whom met criteria for major depression.68 The patients were randomized to either intervention or usual care and results suggested that cancer patients in public sector oncology clinics can benefit from depression treatment. A full-scale trial consisting of 425 low-income ethnic minority patients with cancer is currently under way using this model. Collaborative interventions have also been found to improve patient adherence and prevent relapse.69
Persons with cancer are underserved with respect to receipt of current guideline-level care for major depression. We agree with Williams and Dale41 that patients should not be denied treatment for depression while the efforts to find further evidence of its effectiveness progress. Psychiatrists, as specialty medical consultants, can play a vital role in advocating optimal mental health care for medically ill cancer patient with depression. For psychiatrists treating patients with depression and cancer, it is imperative that the symptoms of depression are identified and that the goal of treatment is remission of depressive symptoms via the modalities mentioned previously. Psychiatrists with medical understanding of the biologic correlations between depression and cancer are in a good position to advocate effective treatment of the patient's comorbid medical conditions. These can include pain and the adverse effects of medical treatments for cancer that can contribute to the patient's experience of depression. In doing so, the patient's psychiatric and medical responses to both depression and cancer treatments may be optimized.
Dr Ell is the Ernest P. Larson Professor of Poverty, Ethnicity, and Health at the School of Social Work of the University of Southern California in Los Angeles. Dr Quon is assistant professor of clinical psychiatry at the Keck School of Medicine of the University of Southern California in Los Angeles. They report that they have no conflicts of interest with the subject matter of this article.
